Interferons in the management of viral hepatitis

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 4, 1998, Pages 229-241

  Zein, Nizar N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cirrhosis; Infection; Liver; Meta analysis; Treatment

Indexed keywords

ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LIVER ENZYME; VIRUS DNA;

CHRONIC HEPATITIS; CLINICAL TRIAL; HEPATITIS B; HEPATITIS C; HUMAN; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; CARCINOMA, HEPATOCELLULAR; CHILD; DRUG COMBINATIONS; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B, CHRONIC; HEPATITIS C; HEPATITIS C, CHRONIC; HEPATITIS, VIRAL, HUMAN; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERONS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; META-ANALYSIS; SEX FACTORS; TRANSAMINASES;

EID: 0031751201     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Simons JN, Leary TP, Dawson GJ et al, Isolation of novel virus-like sequences associated with human hepatitis Native Med (1995) 1: 564-9.
2. Linnen J, Wages J Jr, Zhang-Keck ZY et al, Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science (1996) 271: 505-8.
3. Alter NJ, Nakatsuji Y, Melpolder J et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med (1997) 336: 747-54.
4. Alter MJ, Gallagher M, Morris TT et al, Acute non-A-E hepatitis in the United Slates and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. N Engl J Med (1997) 336: 741-6.
5. Czaja AJ, Abdulkarim AS, Carpenter HA et al, GB virus-C infection in type 1 autoimmune hepatitis. Mayo Clin Proc (1998) 73: 412-8.
6. Dianzani F, Biological basis for the clinical use of interferon. Gut (1993) 34(Suppl): S74-6.
7. Keeffe EB, Hollinger FB, Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepatology (1997) 26(Suppl 1): 101S-7S.
8. Mulley AG, Silverstein MD, Dienstag JL, Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med (1982) 307: 644-52.
9. Shah N, Ostrow D, Altman N, Baker AL, Evolution of acute hepatitis B in homosexual men to chronic hepatitis B. Prospective study of placebo recipients in a hepatitis B vaccine trial. Arch Intern Med (1985) 145: 881-2.
10. Margolis HS, Alter MJ, Hadler SC, Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis (1991) 11: 84-92.
11. Di Bisceglie AM, Rustgi VK, Hoofnagle JH et al, NEH Conference. Hepatocellular Carcinoma. Ann Intern Med (1988) 108: 390-401.
12. Seeff LB, Natural history of viral hepatitis, type C. Semin Gastrointest Dis (1995) 6: 20-7.
13. Bruix J, Barrera JM, Calvet X et al, Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet (1989) ii: 1004-6.
14. Colombo M, Kuo G, Choo QL et al, Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet (1989) ii: 1006-8.
15. Hasan F, Jeffers LJ, De Medina M et al, Hepatitis C-associated hepatocellular carcinoma. Hepatology (1990) 12(Pt 1): 589-91.
16. Kew MC, Houghton M, Choo QL, Kuo G, Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet (1990) 335: 873-4.
17. Kiyosawa K, Sodeyama T, Tanaka E et al, Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepalology (1990) 12(Pt 1): 671-5.
18. Nishioka K., Watanabe J, Furuta S et al, A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer (1991) 67: 429-33
19. Seeff LB, Buskell-Bales Z, Wright EC et al, Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med (1992) 327: 1906-11.
20. Isaacs A, Lindenmann J, Virus interference. I. The interferon. Proc R Soc Land (1957) 147: 258-67.
21. Rothstein KD, Monoz SJ, Interferon and other therapies for hepatitis B and hepatitis C infections. Clin Lab Med (1996) 16: 465-91.
22. Jonas MM, Interferon-alpha for viral hepatitis. J Pediatr Gastroenterol Nutr (1996) 23: 93-106.
23. Lengyel P, Biochemistry of interferons and their actions. Annu Rev Biochem (1982) 51: 251-82.
24. Horisberger MA, Staeheli P, Haller O, Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc Natl Acad Sci USA (1983) 80: 1910-14.
25. Heron I, Hokland M, Berg K, Enhanced expression of beta2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA (1978) 75: 6215-19.
26. Tilg H, New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology (1997) 112: 1017-21.
27. Cacciarelli TV, Martinez OM, Gish RG et al, Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa Hepatology (1996) 24: 6-9.
28. Garcia-Monzon C, Garcia-Buey L, Garcia-Sanchez A et al, Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alfa-2b. Gastroenterology (1993) 105: 462-9.
29. Thomas HC, Jacyna M, Waters J, Main J, Virus-host interaction in chronic hepatitis B virus infection. Semin Liver Dis (1988) 8: 342-9.
30. Tassopoulos NC, Hadziyannis SJ, Wright GE, A randomized double-blind placebo-controlled trial of α-interferon in acute type B hepatitis. Hepatology (1989) 10: 576 (abst).
31. Greenberg HB, Pollard RB, Lutwick LI et al, Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med (1976) 295: 517-22.
32. Di Bisceglie AM, Fong TL, Fried MW et al, A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol (1993) 88: 1887-92.
33. Hoofnagle JH, Peters M, Mullen KD et al, Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology (1988) 95: 1318-25.
34. Feinman SV, Berris B, Sooknanan R et al, Effects of interferon-alpha therapy on serum and liver HBV DNA in patients with chronic hepatitis B. Dig Dis Sci (1992) 37: 1477-82
35. Perrillo RP, Schiff ER, Davis GL et al, A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med (1990) 323: 295-301.
36. Wong DK, Cheung AM, O'Rourke K et al, Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 119: 312-23.
37. Brook MG, McDonald JA, Karayiannis P et al, Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut (1989) 30: 1116-22.
38. Rosina F, Pintus C, Meschievitz C, Rizzetto M, A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology (1991) 13: 1052-6.
39. Gaudin JL, Faure P, Godinet H et al, The French experience of treatment of chronic D type hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver (1995) 15: 45-52.
40. Farci P, Mandas A, Coiana A et al, Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med (1994) 330: 88-94.
41. Lai CL, Lin HJ, Lau JN et al, Effect of a recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med (1991) 78: 155-63.
42. Ruiz-Moreno M, Rua MJ, Molina J et al, Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology (1991) 13: 1035-9.
43. Ruiz-Moreno M, Interferon treatment in children with chronic hepatitis B. J Hepatol (1995) 22(Suppl): 49-51.
44. Ruiz Moreno M, Jimenez J, Porres JC et al, A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion (1990) 45: 26-33.
45. Bruguera M, Amat L, Garcia O et al, Treatment of chronic hepatitis B in children with recombinant alfa interferon. Different response according to age at infection. J Clin Gastroenterol (1993) 17: 296-9.
46. Utili R, Sagnelli E, Gaeta GB et al, Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study. J Hepatol (1994) 20: 163-7.
47. Lai CL, Lok AS, Lin HJ et al, Placebo-controlled trial of recombinant alpha 2-interferon in Chinest HBsAg-carrier children. Lancet (1987) ii: 877-80.
48. Hoofnagle JH, Di Bisceglic AM, Waggoner JG, Park Y, Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology (1993) 104: 1116-21.
49. Perrillo R, Tamburro C, Regenstein F et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology (1995) 109: 908-16.
50. Poterucha JJ, Wiesner RH, Liver transplantation and hepatitis B. Ann Intern Med (1997) 126: 805-7.
51. Dousset B, Conti F, Houssin D, Calmus Y, Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients N Engl J Med (1994) 330: 1160-1.
52. Terrault NA, Holland CC, Ferrell L et al, Interferon alfa for recurrent hepatitis B infection after liver transplantation Lifer Transpl Surg (1996) 2: 132-8.
53. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology (1997) 26(Suppl 1): 2S-10S.
54. Viladomiu L, Genesca J, Esteban JI et al, Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. Hepatology (1992) 15: 767-9.
55. Lampertico P, Rumi M, Romeo R et al, A muiticenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C Hepatology (1994) 19: 19-22
56. Ohnishi K, Nomura F, Nakano M, Interferon therapy for acute posttransfusion non-A, non-B hepatitis: response with respect to anti-hepatitis C virus antibody status. Am J Gastroenterol (1991) 86: 1041-9.
57. Omata M, Yokosuka O, Takano S et al, Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet (1991) 338: 914-15.
58. Hwang SJ, Lee SD, Chan CY et al, A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol (1994) 21: 831-6.
59. Almasio P, Mirto S, Malleo C et al, Recombinant interferon alpha-2B for acute post-transfusion hepatitis in acute myeloid leukemia. Haematologica (1991) 76: 429-30.
60. Hagiwara H, Hayashi N, Kasahara A et al, Three cases of posttransfusion hepatitis C treated with interferon-alpha. Confirmation of a carrier state by detection of hepatitis C virus RNA after interferon therapy. Dig Dis Sci (1992) 37: 631-4.
61. Chemello L, Benvegnù L, Belussi F et al, Pilot study of interferon alpha-2a therapy in preventing chronic evolution of acute hepatitis C. J Hepatol (1990) 11(Suppl 2): S81 (abst).
62. Poynard T, Leroy V, Cohard M et al, Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology (1996) 24: 778-89.
63. Tine F, Magrin S, Craxi A, Pagliaro L, Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol (1991) 13: 192-9.
64. Thomson BJ, Doran M, Lever AM, Webster AD, Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet (1987) i: 539-41.
65. Lockner D, Bratt G, Lindborg A, Tornebohm E, Acute unidentified hepatitis in a hypogammaglobulinaemic patient on intravenous gammaglobulin successfully treated with interferon. Acta Med Scand (1987) 221: 413-15.
66. Hoofnagle JH, Mullen KD, Jones DB et al, Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon, A preliminary report. N Engl J Med (1986) 315: 1575-8.
67. Weiland O, Schvarcz R, Wejstal R et al, Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B hepatitis: interim results of a randomized controlled open study. Scand J Infect Dis (1989) 21: 127-32.
68. Lee CA, Kernoff PB, Karayiannis P, Thomas HC, Interferon therapy for chronic non-A non-B and chronic delta liver disease in haemophilia. Br J Haematol (1989) 72: 235-8.
69. Kiyosawa K, Sodeyama T, Nakano Y et al, Treatment of chronic non-A, non-B hepatitis with human interferon beta: a preliminary study. Antiviral Res (1989) 12: 151-61.
70. Kakumu S, Arao M, Yoshioka K et al, Pilot study of recombinant human alpha-interferon for chronic non-A, non-B hepatitis. Am J Gastroenterol (1989) 84: 40-5.
71. Di Bisceglie AM, Martin P, Kassianides C et al, Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med (1989) 321: 1506-10.
72. Davis GL, Balart LA, Schiff ER et al, Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med (1989) 321: 1501-6.
73. Schvarcz R, Weiland O, Wejstal R et al, A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis (1989) 21: 617-25.
74. Marcellin P, Boyer N, Giostra E et al, Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepawlogy (1991) 13: 393-7.
75. Saez-Royuela F, Porres JC, Moreno A et al, High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology (1991) 13: 327-31.
76. Saracco G, Rosina F, Torrani Cerenzia MR et al, A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol (1990) 11(Suppl 1): S43-9.
77. Nakano Y, Kiyosawa K, Sodeyama T, Tanaka E, Comparative study of clinical, histological, and immunological responses to interferon therapy in type non-A, non-B chronic hepatitis. Am J Gastroenterol (1990) 85: 24-9.
78. Okuno T, Shindo M, Arai K et al, Histological improvement of chronic hepatitis B, and non-A, non-B with interferon treatment: application of a numerical scoring system for evaluating sequential morphologic changes. Gastroenterol Jpn (1990) 25: 70-7.
79. Kakumu S, Arao M, Yoshioka K et al, Recombinant human alpha-interferon therapy for chronic non-A, non-B hepatitis: second report. Am J Gastroenterol (1990) 85: 655-9.
80. Carithers RL Jr, Emerson SS, Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology (1997) 26(Suppl 1): 83S-8S.
81. Zein NN, Rakela J, Interferon therapy in hepatitis C. Semin Gastrointest Dis (1995) 6: 46-53.
82. Causse X, Godinot H, Chevallier M et al, Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology (1991) 101: 497-502.
83. Karino Y, Matsushima T, Saga A et al, Treatment of chronic non-A, non-B hepatitis with interferon. Gastroenterol Jpn (1991) 26(Suppl 3): 234-8.
84. Hakozaki Y, Shirahama T, Katou M et al, A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C. Am J Gastroenterol (1995) 90: 1246-9.
85. Tassopoulos NC, Karvountzis G, Touloumi G et al, Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol (1996) 91: 1734-8.
86. Lindsay KL, Davis GL, Schiff ER et al, Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology (1996) 24: 1034-40.
87. Lin R, Roach E, Zimmerman M et al, Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. J Hepatol (1995) 23: 487-96.
88. Aletreau JM, Results of long term interferon treatment in non A non B/C chronic active hepatitis. The French Group for the Study of NANB/C Chronic Hepatitis Treatment. Gut (1993) 34(Suppl): S112-13.
89. Poynard T, Bedossa P, Chevallier M et al, A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med (1995) 332: 1457-62.
90. Shiffman ML, Hofmann CM, Luketic VA et al, Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology (1996) 24: 21-26.
91. Polus M, Recombinant alpha 2b interferon in the treatment of chronic viral hepatitis C: comparison of 2 schemes, classical and high-dosage [in French]. Rev Méd Liège (1995) 50: 226-9.
92. Lee WM, Therapy of hepatitis C: interferon alfa-2a trials. Hepatology (1997) 26:(Suppl 1): 89S-95S.
93. Farrell GC, Therapy of hepatitis C: interferon alfa-n1 trials. Hepatology (1997) 26(Suppl 1): 96S-100S.
94. Magrin S, Craxi A, Fabiano C et al, Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis. J Med Virol (1992) 38: 200-6.
95. Camps J, Garcia-Granero M, Riezu-Boj JI et al, Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol (1994) 21: 4-11.
96. Yamada G, Takahashi M, Endo H et al, Quantitative hepatitis C virus RNA and liver histology in chronic hepatitis C patients treated with interferon alfa. Gut (1993) 34(Suppl): S133-4.
97. Davis GL, Lau JY, Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology (1997) 26 (Suppl 1): 122S-7S.
98. Schalm SW, Fattovich G, Brouwer JT, Therapy of hepatitis C: patients with cirrhosis. Hepatology (1997) 26(Suppl 1): 128S-32S.
99. Kobayashi Y, Watanabe S, Konishi M et al, Detection of hepatitis C virus RNA by nested polymerase chain reaction in sera of patients with chronic non-A, non-B hepatitis treated with interferon. J Hepatol (1992) 16: 138-44.
100. Hagiwara H, Hayashi N, Mita E et al, Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology (1993) 104: 877-83.
101. Weiland O, Zhang YY, Widell A, Serum HCV RNA levels in pauents with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis (1993) 25: 25-30.
102. Lau JY, Davis GL, Kniffen J et al, Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet (1993) 341: 1501-4.
103. Hagiwara H, Hayashi N, Fusamoto H, Kamada T, Quantitative analysis of hepatitis C virus RNA: relationship between the replicative level and the various stages of the carrier states or the response to interferon therapy. Gastroenterol Jpn (1993) 28(Suppl 5): 48-51.
104. Simmonds P, Alberti A, Alter HJ et al, A proposed system for the nomenclature of hepatitis C viral genotypes Hepatology (1994) 19: 1321-4.
105. Zein NN, Rakela J, Persing DH, Genotype-dependent serologic reactivities in patients infected with hepatitis C virus in the United States. Mayo Clin Proc (1995) 70: 449-52.
106. Zein MN, Rakela J, Krawitt EL et al, Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med (1996) 125: 634-9.
107. Zein NN, Persing DH, Hepatitis C genotypes: current trends and future implications. Mayo Clin Proc (1996) 71: 458-62.
108. Enomoto N, Sakuma I, Asahina Y et al, Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest (1995) 96: 224-30.
109. Patterson JL, Fernandez-Larsson R, Molecular mechanisms of action of ribavirin Rev Infect Dis (1990) 12: 1139-46.
110. Ning Q, Brown D, Parodo J et al, Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves TH1 cytokine production, but inhibits TH2 cytokine response. Hepatology (1996) 24(Suppl): 355A (abst).
111. Dusheiko G, Main J, Thomas H et al, Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol (1996) 25: 591-8.
112. Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH, Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol (1994) 21: 1109-12.
113. Chemello L, Cavalletto L, Bernardinello E et al, The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol (1995) 23(Suppl 2): 8-12.
114. Schvarcz R, Ando Y, Sonnerborg A, Weiland O, Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol (1995) 23(Suppl 2): 17-21.
115. Brillanti S, Garson J, Foli M et al, A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology (1994) 107: 812-17.
116. Schalm SW, Hansen BE, Chemello L et al, Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol (1997) 26: 961-6.
117. Ruiz-Moreno M, Rua MJ, Castillo I et al, Treatment of children with chronic hepatitis C with recombinant interferon-alpha: a pilot study. Hepatology (1992) 16: 882-5.
118. Bortolotti F, Giacchino R, Vajro P et al, Recombinant interferon-alfa therapy in children with chronic hepatitis C. Hepatology (1995) 22: 1623-7.
119. Idilman R, De Maria N, Colantoni A et al, Interferon treatment of cirrhotic patients with chronic hepatitis C. J Viral Hepat (1997) 4: 81-91
120. Bonino F, Oliveri F, Colombatto P, Brunetto MR, Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey. J Viral Hepat (1997) 4(Suppl 2): 79-82.
121. Kuwana K, Ichida T, Kamimura T et al, Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients. J Gastroenterol Hepatol (1997) 12: 149-55.
122. Mazzella G, Accogli E, Sottili S et al, Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol (1996) 24: 141-7.
123. Nishiguchi S, Kuroki T, Nakatani S et al, Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet (1995) 346: 1051-5.
124. Fattovich G, Giustina G, Degos F et al, Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1997) 27: 201-5.
125. Feray C, Samuel D, Gigou M et al, An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatolagy (1995) 22(Pt 1): 1084-9.
126. Wright TL, Combs C, Kim M et al, Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology (1994) 20(Pt 1): 773-9.
127. Marcellin P, Levy S, Erlinger S, Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology (1997) 26(Suppl 1): 133S-6S.
128. Alberti A, Morsica G, Chemello L et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet (1992) 340: 697-8.
129. Antonelli G, Giannelli G, Currenti M et al, Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin Exp Immunol (1996) 104: 384-7.
130. Bonino F, Baldi M, Negro F et al, Clinical relevance of anti-interferon antibodies in the serum of chronic hepatitis C patients treated with interferon-alpha. J Interferon Cytokine Res (1997) 17(Suppl 1): S35-8.
131. Lebovics E, Lantin J, Chaurushia G et al, The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome. Am J Gastroenterol (1995) 90: 951-4.
132. Roffi L, Mels GC, Antonelli G et al, Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology (1995) 21: 645-9.
133. Pascual M, Perrin L, Giostra E, Schifferli JA, Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis (1990) 162: 569-70.
134. Chin CF, Zein NN, Extrahepatic syndromes associated with hepatitis C infection. Gastroenterol Int (1998) 11: 26-35.
135. Ferri C, Greco F, Longombardo G et al, Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheutnatol (1991) 9: 621-4.
136. Misiani R, Bellavita P, Fenili D et al, Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med (1992) 117: 573-7.
137. Agnello V, Chung RT, Kaplan LM, A role for hepatitis C virus infection in type O cryoglobulinemia. N Engl J Med (1992) 327: 1490-5.
138. Lunel F, Musset L, Cacoub P et al, Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage Gastroenterology (1994) 106: 1291-300.
139. Bichard P, Ounanian A, Girard M et al, High prevalence of hepatitis C virus RNA in the supernatant and the cryoprecipitate of patients with essential and secondary type II mixed cryoglobuline-mia. J Hepatol (1994) 21: 58-63.
140. Sansonno D, Cornacchiulo V, Iacobelli AR et al, Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinemia. Hepatology (1995) 21: 305-12.
141. Pawlotsky JM, Ben Yahia M, Andre C et al, Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology (1994) 19: 841-8.
142. Misiani R, Bellavita P, Fenili D et al, Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med (1994) 330: 751-6.
143. Noda K, Enomoto N, Arai K et al. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand J Gastroenterol (1996) 31: 716-22.
144. Mayet WJ, Hess G, Gerken G et al, Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology (1989) 10: 24-8.
145. Lisker-Melman M, Di Bisceglie AM, Usala SJ et al, Development of thyroid disease during therapy of chronic viral hepatitis with Interferon alfa. Gastroenterology (1992) 102: 2155-60.
146. Marcellin P, Pouteau M, Renard P et al, Sustained hypothyroidism induced by recombinant alpha interferon m patients with chronic hepatitis C. Gut (1992) 33: 855-6.
147. Weiland O, Cheri M, Lindh G et al, Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection. Scand J Infect Dis (1995) 27: 319-24.
148. Picciotto A, Callea F, Varagona G et al, Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses. Liver (1995) 15: 20-4.
149. Renault PF, Hoofnagle JH, Park Y et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med (1987) 147: 1577-80.
150. Louis-Jacques O, Olson AD, Cost-benefit analysis of interferon therapy in children with chronic active hepatitis B. J Pediatr Gastroenterol Nutr (1997) 24: 25-32.
151. Kim WR, Poterucha JJ, Hermans JE et al, Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med (1997) 127: 866-74.